- Home
- GMAB vs CLX Comparison
GMAB vs CLX Comparison
Compare GMAB & CLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- CLX
- Stock Information
- Founded
- GMAB 1999
- CLX 1913
- Country
- GMAB Denmark
- CLX United States
- Employees
- GMAB N/A
- CLX N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- CLX Specialty Chemicals
- Sector
- GMAB Health Care
- CLX Consumer Discretionary
- Exchange
- GMAB Nasdaq
- CLX Nasdaq
- Market Cap
- GMAB 13.7B
- CLX 15.1B
- IPO Year
- GMAB N/A
- CLX N/A
- Fundamental
- Price
- GMAB $21.45
- CLX $126.53
- Analyst Decision
- GMAB Buy
- CLX Hold
- Analyst Count
- GMAB 8
- CLX 12
- Target Price
- GMAB $37.80
- CLX $148.83
- AVG Volume (30 Days)
- GMAB 1.6M
- CLX 2.0M
- Earning Date
- GMAB 08-07-2025
- CLX 07-31-2025
- Dividend Yield
- GMAB N/A
- CLX 3.82%
- EPS Growth
- GMAB 276.80
- CLX 188.97
- EPS
- GMAB 18.36
- CLX 5.57
- Revenue
- GMAB $3,230,902,140.00
- CLX $7,019,000,000.00
- Revenue This Year
- GMAB $747.74
- CLX $0.42
- Revenue Next Year
- GMAB $14.81
- CLX N/A
- P/E Ratio
- GMAB $11.66
- CLX $22.72
- Revenue Growth
- GMAB 25.43
- CLX N/A
- 52 Week Low
- GMAB $17.24
- CLX $117.35
- 52 Week High
- GMAB $28.56
- CLX $171.37
- Technical
- Relative Strength Index (RSI)
- GMAB 53.47
- CLX 52.81
- Support Level
- GMAB $20.23
- CLX $123.53
- Resistance Level
- GMAB $21.90
- CLX $128.79
- Average True Range (ATR)
- GMAB 0.35
- CLX 2.11
- MACD
- GMAB 0.06
- CLX 1.12
- Stochastic Oscillator
- GMAB 73.52
- CLX 80.20
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About CLX Clorox Company (The)
Since its start more than 100 years ago, Clorox has expanded to operate in a variety of consumer products categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.